Solid Biosciences insider plans 12,616-share sale

Solid Biosciences shareholder Brooks Gabriel filed a Rule 144 notice to sell 12,616 shares of common stock through E*TRADE on NASDAQ, with an aggregate market value of $81,267.65.

Accepted by SEC EDGAR 02/04/2026 - 07:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Solid Biosciences shareholder Brooks Gabriel filed a Rule 144 notice to sell 12,616 shares of common stock through E*TRADE on NASDAQ, with an aggregate market value of $81,267.65. The filing shows 82,569,192 shares of common stock outstanding.

The 12,616 shares were acquired the same day via settlement of vested restricted stock units as compensation from the issuer. The notice also reports that Gabriel sold 28,335 shares of common stock in a prior transaction on 02/02/2026, generating gross proceeds of $182,389.56.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SLDB Rule 144 filing by Brooks Gabriel disclose?

The filing shows Brooks Gabriel intends to sell 12,616 shares of Solid Biosciences common stock under Rule 144. These shares were acquired via vested restricted stock units and will be sold through E*TRADE on NASDAQ, with an indicated market value of $81,267.65.

How many Solid Biosciences (SLDB) shares are being sold in this notice?

The notice covers a planned sale of 12,616 shares of Solid Biosciences common stock. The shares are to be sold through E*TRADE on NASDAQ, with the table showing an aggregate market value of $81,267.65 for this transaction.

How were the SLDB shares in this Rule 144 filing acquired?

The 12,616 Solid Biosciences shares were acquired on 02/04/2026 through settlement of vested restricted stock units. The filing describes the nature of the acquisition as compensation from the issuer, rather than a cash purchase in the open market.

What prior Solid Biosciences stock sales by Brooks Gabriel are disclosed?

The document reports that Brooks Gabriel sold 28,335 shares of Solid Biosciences common stock on 02/02/2026. Those sales generated gross proceeds of $182,389.56, and are listed as securities sold during the past three months.

How many Solid Biosciences (SLDB) shares are outstanding in this filing?

The securities information table lists 82,569,192 shares of Solid Biosciences common stock outstanding. This figure provides context for the size of the planned 12,616-share Rule 144 sale relative to the company’s total common stock base.

Which broker and exchange are used for this SLDB Rule 144 sale?

The notice identifies E*TRADE Financial Corporation as the broker for the transaction. The shares of Solid Biosciences common stock are expected to be sold on the NASDAQ exchange, with an approximate sale date listed as 02/04/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001997809
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Solid Biosciences Inc.
SEC File Number	001-38360
Address of Issuer	500 Rutherford Avenue Charlestown MASSACHUSETTS 02129
Phone	(617)-337-4680
Name of Person for Whose Account the Securities are To Be Sold	Brooks Gabriel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	12616	81267.65	82569192	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/04/2026	Settlement of vested restricted stock units	Issuer			12616	02/04/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brooks Gabriel 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/02/2026	28335	182389.56

144: Remarks and Signature

Remarks	The sale reported on this Form 144 was made to cover witholding taxes following the vesting of previously granted performance stock units pursuant to a durable sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-cover-election. The sale does not represent a discretionary trade by Dr. Brooks.
Date of Notice	02/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)